Simon Frey1, Tom Stargardt2, Udo Schneider3, Jonas Schreyögg2. 1. Hamburg Center for Health Economics, Universität Hamburg, Hamburg, Germany. simon.frey@uni-hamburg.de. 2. Hamburg Center for Health Economics, Universität Hamburg, Hamburg, Germany. 3. Techniker Krankenkasse, Hamburg, Germany.
Abstract
BACKGROUND: Cystic fibrosis (CF) is a genetic disorder that is most common in white children and young adults. Long-term survival has improved steadily and will likely increase with the recent introduction of neonatal screening and causative treatment. However, these advances have substantial economic consequences for healthcare systems and payers. OBJECTIVE: This study aims to determine the economic burden of CF and to elucidate the structure of costs and the distribution of resources for different subpopulations, treatment strategies and sites of care for CF in Germany. METHODS: We conducted an observational cohort study to evaluate the economic burden of CF and the costs of treatment within different CF substrata from a payer perspective. Using claims data from a large German sickness fund, we identify the causal effect of CF on costs, service utilisation, and premature mortality. We compare the outcomes of a CF and a control group using entropy balancing and regression techniques, conduct further analyses for the CF group to gain insight into the economic burden associated with different levels of disease severity, and analyse pharmaceutical expenditures by collecting all CF-related expenses on outpatient drug treatment from the sickness fund database. RESULTS: Direct medical costs caused by CF in Germany in 2016 average €17,551 per patient-year and appear to be mainly driven by the cost of outpatient drug prescriptions (€12,869). We estimate that the national burden of disease totals €159 million. Costs increase with disease severity and related complications. If all eligible CF patients in the German population were to receive CF mutation-specific drugs, the economic burden of disease would more than triple to €594 million. CONCLUSION: CF has a constant and wide-ranging economic impact on payers, with considerable differences in the distribution of costs and service utilisation between younger and older patients as well as mild vs. severe patients. Pharmaceutical expenses will increase in the future as causative treatment gains importance. We encourage the use of a control group approach for burden-of-disease studies to be able to identify causal effects and thus to obtain more precise estimates.
BACKGROUND:Cystic fibrosis (CF) is a genetic disorder that is most common in white children and young adults. Long-term survival has improved steadily and will likely increase with the recent introduction of neonatal screening and causative treatment. However, these advances have substantial economic consequences for healthcare systems and payers. OBJECTIVE: This study aims to determine the economic burden of CF and to elucidate the structure of costs and the distribution of resources for different subpopulations, treatment strategies and sites of care for CF in Germany. METHODS: We conducted an observational cohort study to evaluate the economic burden of CF and the costs of treatment within different CF substrata from a payer perspective. Using claims data from a large German sickness fund, we identify the causal effect of CF on costs, service utilisation, and premature mortality. We compare the outcomes of a CF and a control group using entropy balancing and regression techniques, conduct further analyses for the CF group to gain insight into the economic burden associated with different levels of disease severity, and analyse pharmaceutical expenditures by collecting all CF-related expenses on outpatient drug treatment from the sickness fund database. RESULTS: Direct medical costs caused by CF in Germany in 2016 average €17,551 per patient-year and appear to be mainly driven by the cost of outpatient drug prescriptions (€12,869). We estimate that the national burden of disease totals €159 million. Costs increase with disease severity and related complications. If all eligible CF patients in the German population were to receive CF mutation-specific drugs, the economic burden of disease would more than triple to €594 million. CONCLUSION: CF has a constant and wide-ranging economic impact on payers, with considerable differences in the distribution of costs and service utilisation between younger and older patients as well as mild vs. severe patients. Pharmaceutical expenses will increase in the future as causative treatment gains importance. We encourage the use of a control group approach for burden-of-disease studies to be able to identify causal effects and thus to obtain more precise estimates.
Authors: Jenna Sykes; Sanja Stanojevic; Christopher H Goss; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Anne L Stephenson Journal: J Clin Epidemiol Date: 2015-10-03 Impact factor: 6.437
Authors: Abaigeal D Jackson; Andrew L Jackson; Godfrey Fletcher; Gerardine Doyle; Mary Harrington; Shijun Zhou; Fiona Cullinane; Charles Gallagher; Edward McKone Journal: Pharmacoeconomics Date: 2017-10 Impact factor: 4.981
Authors: Patrick D Mauldin; Cassandra D Salgado; Ida Solhøj Hansen; Darshana T Durup; John A Bosso Journal: Antimicrob Agents Chemother Date: 2009-10-19 Impact factor: 5.191
Authors: Ulrich Baumann; Christiane Stocklossa; Wolfgang Greiner; Johann-Matthias Graf von der Schulenburg; Horst von der Hardt Journal: J Cyst Fibros Date: 2003-06 Impact factor: 5.482
Authors: Teja Thorat; Lisa J McGarry; Machaon M Bonafede; Brendan L Limone; Jaime L Rubin; Krutika Jariwala-Parikh; Michael W Konstan Journal: Pediatr Pulmonol Date: 2021-07-07